Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Dec 21:8:130.
doi: 10.1186/s13045-015-0227-0.

Bispecific antibodies and their applications

Gaowei Fan  1   2 , Zujian Wang  3 , Mingju Hao  4   5 , Jinming Li  6   7
Affiliations
Review

Bispecific antibodies and their applications

Gaowei Fan et al. J Hematol Oncol. .

Abstract

Bispecific antibodies (BsAbs) recognize two different epitopes. This dual specificity opens up a wide range of applications, including redirecting T cells to tumor cells, blocking two different signaling pathways simultaneously, dual targeting of different disease mediators, and delivering payloads to targeted sites. The approval of catumaxomab (anti-EpCAM and anti-CD3) and blinatumomab (anti-CD19 and anti-CD3) has become a major milestone in the development of bsAbs. Currently, more than 60 different bsAb formats exist, some of them making their way into the clinical pipeline. This review summarizes diverse formats of bsAbs and their clinical applications and sheds light on strategies to optimize the design of bsAbs.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Molecular formats of bispecific antibodies
Fig. 2
Fig. 2
Triomab® antibodies redirect T cells and other accessory cells to a tumor cell
Fig. 3
Fig. 3
BiTE® antibodies redirect T cells to a tumor cell
See this image and copyright information in PMC

References

    1. Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. mAbs. 2015;7(1):9–14. doi: 10.4161/19420862.2015.989042. - DOI - PMC - PubMed
    1. Suresh T, Lee LX, Joshi J, Barta SK. New antibody approaches to lymphoma therapy. J Hematol Oncol. 2014;7(1):58. doi: 10.1186/s13045-014-0058-4. - DOI - PMC - PubMed
    1. Kontermann R. Dual targeting strategies with bispecific antibodies. mAbs. 2012;4(2):182–97. doi: 10.4161/mabs.4.2.19000. - DOI - PMC - PubMed
    1. Regales L, Gong Y, Shen R, de Stanchina E, Vivanco I, Goel A, et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest. 2009;119(10):3000–10. - PMC - PubMed
    1. Dhimolea E, Reichert JM. World bispecific antibody summit, September 27–28, 2011, Boston, MA. mAbs. 2012;4(1):4–13. doi: 10.4161/mabs.4.1.18821. - DOI - PMC - PubMed

Publication types

MeSH terms